Search results
Results from the WOW.Com Content Network
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. [6] Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.
Filgrastim is a recombinant form of the naturally occurring granulocyte colony-stimulating factor (G-CSF). [21] It works by stimulating the body to increase neutrophil production. [21] Filgrastim was approved for medical use in the United States in 1991. [21] It is on the World Health Organization's List of Essential Medicines.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
Nine of them cost more than $2 million. A tenth, approved in November, is predicted to run about $3.8 million, just shy of the most expensive, also approved last year, which costs $4.25 million a ...
In the European Union, no unique identifier of a biosimilar medicine product is required, as the same rules are followed as for all biologics. [ citation needed ] The US decided on a different approach, requiring the assignment of a four-letter suffix to the nonproprietary name of the original product to distinguish between innovator drugs and ...
Acute pain — sudden or urgent pain that results from injury, trauma or surgery — affects more than 80 million Americans annually and is the most common reason for emergency department visits.
Within the year of 2014, the cost of prescriptions had increased by at least 11.4% and 58% within the last eight years. The average cost for a month supply of brand-name drugs can run up to a couple of hundred US dollars, whereas in Canada and Great Britain the same medication could cost up to $40 US dollars.
Oncologists in the US have also used the BEACOPP regimen relatively less for cost reasons: Twice as many infusion per cycle relative to ABVD ; Requirement for G-CSF support, which was under patent protection in the US as late as 2013 (as Neupogen by Amgen), [ 4 ] while that patent protection expired in the EU in 2008; [ 5 ]